Michaël Lugez has been appointed CEO of Celgene Nordic, replacing Nicolas Verbeke who will remain at the company as General Manager Celegne in central Europe and northern Europe.
Lugez has been working at Celgene since 2014 and has most recently held a position as Head of Business Inflammation and Immunology in France.
“Celgene Nordic is in a positive growth phase and it is with great humble I take on the role as CEO. I have long experience from Celgene as a company and I look forward to learn more about the Nordic countries’ healthcare markets. We will continue to invest in clinical research in the Nordics and within the next couple of years I hope we will be able to launch both more pharmaceuticals as well as new indications of exisiting pharmaceuticals,” says Lugez.
Two other appointments
The company has also appointed Lars Nicklasson as Head of Corporate Affairs and Market Access and Björn Hellström as Head of the company’s new business area Cell and Gene therapy with the field of blood cancer, CAR-T. Both of them have previously held other positions within the company, in Switzerland and in Stockholm, Sweden.
Today, Celgene is supporting around 70 clinical trials in the Nordic region.
Photo of Michaël Lugez: Celgene